Proteomics analysis of cardiac extracellular matrix remodeling in a porcine model of ischemia/reperfusion injury

J Barallobre-Barreiro, A Didangelos, FA Schoendube… - Circulation, 2012 - ahajournals.org
Circulation, 2012ahajournals.org
Background—After myocardial ischemia, extracellular matrix (ECM) deposition occurs at the
site of the focal injury and at the border region. Methods and Results—We have applied a
novel proteomic method for the analysis of ECM in cardiovascular tissues to a porcine model
of ischemia/reperfusion injury. ECM proteins were sequentially extracted and identified by
liquid chromatography tandem mass spectrometry. For the first time, ECM proteins such as
cartilage intermediate layer protein 1, matrilin-4, extracellular adipocyte enhancer binding …
Background
After myocardial ischemia, extracellular matrix (ECM) deposition occurs at the site of the focal injury and at the border region.
Methods and Results
We have applied a novel proteomic method for the analysis of ECM in cardiovascular tissues to a porcine model of ischemia/reperfusion injury. ECM proteins were sequentially extracted and identified by liquid chromatography tandem mass spectrometry. For the first time, ECM proteins such as cartilage intermediate layer protein 1, matrilin-4, extracellular adipocyte enhancer binding protein 1, collagen α-1(XIV), and several members of the small leucine-rich proteoglycan family, including asporin and prolargin, were shown to contribute to cardiac remodeling. A comparison in 2 distinct cardiac regions (the focal injury in the left ventricle and the border region close to the occluded coronary artery) revealed a discordant regulation of protein and mRNA levels; although gene expression for selected ECM proteins was similar in both regions, the corresponding protein levels were much higher in the focal lesion. Further analysis based on >100 ECM proteins delineated a signature of early- and late-stage cardiac remodeling with transforming growth factor-β1 signaling at the center of the interaction network. Finally, novel cardiac ECM proteins identified by proteomics were validated in human left ventricular tissue acquired from ischemic cardiomyopathy patients at cardiac transplantation.
Conclusion
Our findings reveal a biosignature of early- and late-stage ECM remodeling after myocardial ischemia/reperfusion injury, which may have clinical utility as a prognostic marker and modifiable target for drug discovery.
ahajournals.org